I'm still long $SGMO and a buyer not seller currently. Here's a tweet stream with my views and why I left the IV board for mental health and the need to eliminate all the emotive noise it generates. 1/n

SM has said numerous times that GT is not durable. He explained why the $SGMO was not focused on GT and was moving on from $PFE collab to work on curative wave 2 and 3. Said no one knows why $BMRN waning occurs but later said GT only a 5 to 10 yr drug. 2/n

SM compared ABR at $AVRO to weak protein expression saying that science doesn't yet understand the connection. continued to say wait for longer term duration data to see whether HemA could differentiate. Now $SGMO sees similar waning but better ABR and safety than Valrox 3/n

$SGMO collaborates to share risk. The HemA value didn't plunge. It remains likely best in class w/ high probability approval odds. The milestones are all likely to be paid against zero future costs. Royalty NPV did decline as market penetration likely dropped 4/n

Why is $SGMO "moving on from $PFE"? Pretty clear-Pfizer was not the best neurology partner which is the curative future SGMO is pursuing. $BIIB and $NVS are both miles ahead of pfizer. 5/n

why so long to sign gene regulation collabs? See 3 yr effort in directed evolution. With foundation built needs more to go after all the new targets $NVS $BIIB brought to table. New SVP Delivery Sciences being recruited. Watch new website 6/n
https://www.sangamo.com/genomic-therapies/delivery

Yesterday sell off IMO was NOT due to HemA. It was due to great $CRSP data for SCD. I believe SM when he said issues were NOT ZF ex vivo editing. If true, $SGMO executed but $SNY is working thru issues. 7/n

Despite hundreds of complaints that $SGMO isn't progressing with $GILD the reality is that sangamo is supporting not leading. And gilead has always looked to push for cures and better science. 8/n

Again #GeneTherapy has a limited therapeutic value. Gene Regulation is far longer-maybe lifelong.
9/n

$SGMO will not a leader in #GeneTherapy given hundreds of INDs. $PFE will be a leader due to logistics, mfg, reg footprint, etc. The 5-10 year solution is what can be done and they have many preclinic candidates which puts significance on HemA
10/n https://seekingalpha.com/article/4392067-pfizer-new-growth-foundation-in-genomic-medicine

$SGMO will be a leader in curative solutions and is undervalued today. This stock is a long term investment with lots of trading opportunities for those that pay attention. Saying they screwed up because the market got ahead of the company in 2017-8 ignores reality.
11/n end